Peter Youssef
About
In The Last Decade
Peter Youssef
86 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 106
- Rheumatology 1.3k
- Pulmonary and Respiratory Medicine 817
- Molecular Biology 739
- Pathology and Forensic Medicine 719
- Immunology 613
Countries citing papers authored by Peter Youssef
This map shows the geographic impact of Peter Youssef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Youssef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Youssef more than expected).
Fields of papers citing papers by Peter Youssef
This network shows the impact of papers produced by Peter Youssef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Youssef. The network helps show where Peter Youssef may publish in the future.
Co-authorship network of co-authors of Peter Youssef
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Youssef. A scholar is included among the top collaborators of Peter Youssef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Youssef. Peter Youssef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 5 | |
| 3 | 2 | |
| 4 | 2 | |
| 5 | 1 | |
| 6 | 2 | |
| 7 | 28 | |
| 8 | 91 | |
| 9 | The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. | 16 |
| 10 | Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. | 28 |
| 11 | 1 | |
| 12 | 5 | |
| 13 | 1 | |
| 14 | A retrospective chart review of mabthera (rituximab) for rheumatoid arthritis (Ra) in Australian rheumatology practice | 1 |
| 15 | SAFETY AND TOLERABILITY OF TOCILIZUMAB IN LONG-TERM EXTENSION STUDIES OF RHEUMATOID ARTHRITIS | 1 |
| 16 | MORTALITY AND CAUSES OF DEATH IN AN AUSTRALIAN SYSTEMIC SCLEROSIS COHORT | 1 |
| 17 | FREQUENCY, CLINICAL CHARACTERISTICS AND RISK FACTORS FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS | 3 |
| 18 | 91 | |
| 19 | Effects of pulse methylprednisolone on macrophage chemotactic protein-1 and macrophage inflammatory protein-1alpha in rheumatoid synovium. | 13 |
| 20 | Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. | 121 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.